Phathom Pharmaceuticals to Present at Two Key Investor Conferences in September
Event summary
- Phathom Pharmaceuticals to participate in Cantor Global Healthcare Conference on September 9, 2026, with a fireside chat at 10:55 am EDT.
- Company to also present at H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, with a fireside chat at 3:30 pm EDT.
- Management to engage in one-on-one meetings throughout both conferences.
- Live webcasts and archived recordings available on Phathom's investor relations website for 90 days post-event.
The big picture
Phathom's participation in high-profile investor conferences underscores its push to strengthen relationships with key stakeholders amid a competitive landscape in gastrointestinal treatments. The focus on vonoprazan's commercialization and development pipeline comes as the company seeks to solidify its position in a market dominated by established players and emerging therapies. Investors will be watching for signals on execution risk and the potential for expanded indications.
What we're watching
- Strategic Messaging
- How Phathom positions its vonoprazan portfolio to address investor concerns about market penetration and competitive differentiation.
- Pipeline Updates
- Whether management provides new insights on development timelines or regulatory milestones for vonoprazan in additional indications.
- Market Sentiment
- The pace at which investor interest translates into tangible engagement or follow-up actions post-conference.